ATS 2019 Virtual Final Program

3:17 PGD2 Receptor 2 Antagonism Reduces Airway Smooth Muscle Mass in Asthma: Mechanistic Insights C.E. Brightling, BSc(Hons), MBBS, PhD, Leicester, United Kingdom 3:35 The Ceramide/Sphingosine-1-Phosphate Rheostat: Surviving Toxic Insult in the Lung I. Petrache, MD, ATSF, Denver, CO 3:53 Towards Targeting Pro-Resolution Pathways of Airway Inflammation in Asthma and COPD B.D. Levy, MD, ATSF, Boston, MA BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 A86 MECHANOPHARMACOLOGY OF AIRWAY AND AIRWAY SMOOTH MUSCLE Assembly on Respiratory Structure and Function 2:15 p.m. - 4:15 p.m. KBHCCD Ballroom D One (Level 3) Target Audience Basic scientists and clinicians interested in lung function and airway diseases Objectives At the conclusion of this session, the participant will be able to: • appreciate the influence of mechanical forces on pharmacological responses of lung tissue; • gain new findings about the synergistic effect of bronchodilators have on airways in combination with mechanical perturbation and agents that modify airway stiffness; • improve understanding on pharmacology of tissues and organs which are constantly under the influence of mechanical forces. Traditional pharmacological studies do not take into account the effects of mechanical movement on the drug-receptor interaction. Airways in a living lung are constantly under the influence of cyclic stress and strain due to breathing. Increasingly it has been shown that a dynamic mechanical environment has a significant impact of airway and airway smooth muscle behavior, and that the traditional “static” pharmacology offers very limited understanding on how airways respond to bronchoconstrictor and bronchodilator stimulation. In this session the audience will be introduced to a new branch of science- mechanopharmacology, and learn how mechanical forces modulate airway properties and drug targets for altering the properties. Chairing: C. Seow, PhD, ATSF, Vancouver, Canada P.B. Noble, PhD, Perth, Australia 2:15 Therapeutic Implications of Increased Airway Stiffness in Obstructive Disease P.B. Noble, PhD, Perth, Australia 2:35 Synergistic Effect of Bronchodilators on Airway Smooth Muscle in the Presence of Rho-Kinase Inhibitor and Mechanical Perturbation L. Wang, PhD, Vancouver, Canada 2:55 Mechanical Activation of TGFbeta in Contracted and Cyclically Stretched Airways B.S. Brook, PhD, DrPH, Nottingham, United Kingdom 3:15 The Duration Between Deep Inspirations on the Rate of Airway Renarrowing Y. Bossé, PhD, Québec, Canada 3:35 TGFbeta Signalling: Complexity Creates Opportunities for Safer Drug Targeting A. Stewart, PhD, Melbourne, Australia 3:55 Traction Force Screening for Bronchodilator Drug Discovery R. Krishnan, PhD, MS, Boston, MA BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 A87 KNOWLEDGE GAPS AND PATHWAYS FORWARD IN RV FAILURE RESEARCH: RECOMMENDATIONS FROM AN OFFICIAL ATS RESEARCH STATEMENT ON RV FAILURE Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care; Pediatrics; Respiratory Cell and Molecular Biology 2:15 p.m. - 4:15 p.m. KBHCCD Room D167/D174 (Level 1) Target Audience Researchers, critical care physicians, pulmonologists, cardiologists, emergency medicine physicians, anesthesiologists, cardiovascular surgeons, pediatricians, nurses, respiratory therapists, students, residents, fellows, grad students, postdocs Objectives At the conclusion of this session, the participant will be able to: • understand the mechanisms underlying adaptive versus maladaptive RV adaptation to pulmonary vascular load including role of fibrosis, angiogenesis, metabolic shifts; • understand the role of plasma and/or imaging biomarkers (by echocardiography and cardiac MRI) that could be used to accurately evaluate RV function, perfusion, and RV-PA coupling and as end-points in clinical trials; • identify potential novel therapies aimed at targeting RV myocardial contractility (e.g. calcium-sensitizing agents targeting sarcoplasmic reticulum and/or sarcomere function). This symposium will discuss key recommendations from an Official ATS Research Statement generated by a working group of 20 international experts from the Assemblies on Pulmonary Circulation and Critical Care. The document has been accepted for publication and will be published in the AJRCCM in the Summer or early Fall of 2018. This symposium will summarize the document and highlight the major knowledge gaps and research priorities to be addressed in the next five years in the areas of epidemiology, pathophysiology, phenotyping, diagnosis, risk stratification and treatment of acute and chronic RV failure. The recommendations will serve as a roadmap for junior and senior investigators interested in cardiopulmonary research. ATS 2019 • Dallas, TX SUNDAY • MAY 19 101 SUNDAY AFTERNOON